Herpes Zoster Clinical Trial
Official title:
Risk Factors Analysis of Anxiety and Depression in Patients With Herpes Zoster Neuralgia and Characteristics of Serum Biomarkers and Functional Brain Magnetic Resonance Changes
The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.
| Status | Not yet recruiting |
| Enrollment | 600 |
| Est. completion date | December 2026 |
| Est. primary completion date | May 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: 1. Age more than 18 years old 2. Diagnosed as herpes zoster neuralgia 3. Signing informed consent Exclusion Criteria: 1. Unable to complete the scale assessment 2. History of mental illness |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Huazhong University of Science and Technology |
Du J, Sun G, Ma H, Xiang P, Guo Y, Deng Y, Li S, Li X. Prevalence and Risk Factors of Anxiety and Depression in Patients with Postherpetic Neuralgia: A Retrospective Study. Dermatology. 2021;237(6):891-895. doi: 10.1159/000512190. Epub 2020 Dec 16. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | HADS score | Enrolled patients will be first evaluated by Hospital Anxiety and Depression Scare questionaire and according to the HADS score, patients will be divided to group with anxiety/depression and group without anxiety/depression. | during hospital stay, average of 1 week | |
| Secondary | Interleukin (IL)-1ß plasma level | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-1ß (pg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | IL-2 receptor plasma level | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-2 (u/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | IL-6 plasma level | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-6 (pg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | IL-8 plasma level | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-8 (pg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | IL-10 plasma level | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-10 (pg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | Interferon(INF)-a plasma level | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines INF-a (pg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | Brain-derived neurotrophic factor (BDNF) plasma level | Blood sample will be obtained from enrolled patients and the plasma level of BDNF(pg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | C-reactive protein (CRP) plasma level | Blood sample will be obtained from enrolled patients and the plasma level of CRP(mg/ml)will be tested. | during hospital stay, average of 1 week | |
| Secondary | Area under curve (AUC) of topological metrics of functional brain magnetic resonance imaging | Functional brain magnetic resonance imaging will be performed in patients with anxiety or depression, and area under curve (AUC) of topological metrics including Eglob,Eloc,Cp,Lp,?,? and s will be calculated and analyzed. | during hospital stay, average of 1 week |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03120364 -
Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
|
Phase 3 | |
| Completed |
NCT01165203 -
Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
|
Phase 2 | |
| Recruiting |
NCT06088745 -
A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine
|
Phase 3 | |
| Completed |
NCT01385566 -
A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)
|
Phase 1 | |
| Completed |
NCT01137669 -
ZOSTAVAX® in Renal Transplant Patients
|
Phase 1 | |
| Completed |
NCT01911065 -
T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020
|
Phase 4 | |
| Completed |
NCT00550745 -
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
|
Phase 4 | |
| Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
| Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
| Completed |
NCT00231816 -
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
|
Phase 3 | |
| Completed |
NCT02852876 -
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
|
Phase 1 | |
| Completed |
NCT05082688 -
Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)
|
Phase 2 | |
| Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
| Active, not recruiting |
NCT04091451 -
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles
|
Phase 3 | |
| Completed |
NCT02519855 -
Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
|
Phase 3 | |
| Completed |
NCT04523246 -
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
|
Early Phase 1 | |
| Completed |
NCT05047770 -
A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine
|
Phase 3 | |
| Completed |
NCT03314103 -
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age
|
Phase 3 | |
| Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
| Completed |
NCT01954251 -
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
|
Phase 3 |